$-0.10 EPS Expected for Critical Outcome Technologies Inc. (COTQF); Nuveen Intermediate Duration Quality Municipal Term Fund Has 1.78 Sentiment

December 6, 2017 - By Adrian Mccoy

Analysts expect Critical Outcome Technologies Inc. (OTCMKTS:COTQF) to report $-0.10 EPS on December, 18.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.1 EPS. The stock decreased 9.67% or $0.09 during the last trading session, reaching $0.8. About shares traded. Critical Outcome Technologies Inc. (OTCMKTS:COTQF) has 0.00% since December 6, 2016 and is . It has underperformed by 16.70% the S&P500.

The stock decreased 0.31% or $0.04 during the last trading session, reaching $12.91. About 31,388 shares traded or 29.55% up from the average. Nuveen Intermediate Duration Quality Municipal Term Fund (NIQ) has 0.00% since December 6, 2016 and is . It has underperformed by 16.70% the S&P500.

Rivernorth Capital Management Llc holds 0.4% of its portfolio in Nuveen Intermediate Duration Quality Municipal Term Fund for 406,390 shares. Newman Dignan & Sheerar Inc. owns 20,623 shares or 0.15% of their US portfolio. Moreover, Usca Ria Llc has 0.12% invested in the company for 69,971 shares. The Georgia-based Greatmark Investment Partners Inc. has invested 0.08% in the stock. Karpus Management Inc., a New York-based fund reported 117,170 shares.

Critical Outcome Technologies Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company has market cap of $13.67 million. The Company’s lead compound is COTI-2, a novel small molecule activator of misfolded mutant p53 proteins, which is in Phase I clinical trial for the treatment of gynecologic cancers, as well as head and neck squamous cell carcinoma. It currently has negative earnings. The firm also develops COTI-219, a novel oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS function; drug candidates for the treatment of acute myelogenous leukemia, SOX9, MRSA, multiple sclerosis, and AlzheimerÂ’s disease; and HIV integrase inhibitors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Adrian Mccoy




Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: